Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is an intracellular pattern recognition receptor that detects bacterial peptidoglycan fragments, specifically muramyl dipeptide (MDP). Upon MDP binding, NOD2 oligomerizes, recruits RIPK2, and activates downstream pathways like NF-kappaB and MAPKs, leading to pro-inflammatory cytokine production. Mutations in NOD2 are associated with Crohn's disease and other inflammatory conditions, making it a therapeutic target for modulating the innate immune response.
NOD2 activators and inhibitors modulate the inflammatory response by targeting the NOD2 signaling pathway.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleotide-binding oligomerization domain-containing protein 2 (NOD2).